Objective: To characterize the correlates of protection from systemic infection in a vaccinated rhesus macaque, RAt-9, which had been challenged sequentially with two related clade C simian/human immunodeficiency viruses (SHIV-Cs) yet remained aviremic for more than 5 years despite indirect evidence of cryptic infection.
Introduction
Identifying correlates of protection against immunodeficiency virus infection remains a major goal and is important for rational AIDS vaccine design. Extensive efforts are underway to identify such correlates in individuals within the moderately successful RV144 trial [1] . Alternatively, vaccinated nonhuman primates that have resisted viral infection or had reduced pathogenesis after exposure to simian immunodeficiency viruses (SIVs) or chimeric simian/human immunodeficiency viruses (SHIVs) have also been used to examine potential correlates [2] [3] [4] . Understanding individual virus-host interactions is crucial to define protective parameters, including host genetics as well as innate and adaptive immunity.
We previously described a vaccinated rhesus macaque, RAt-9, that remained aviremic following sequential mucosal challenges with two related yet distinct R5 clade C SHIVs (SHIV-Cs) [5] . RAt-9 was vaccinated with SIVmac239 Gag-Pol particles, HIV Tat and trimeric HIV clade C (HIV-C) 1084i [6] gp160, and orally challenged once with low-dose, tier 1 SHIV-1157ip. Env of the immunogen and first challenge virus were derived from primary HIV-Cs isolated from different infants within the same Zambian cohort of HIV-C þ mother-infant pairs [7] ; the amino acid sequences of the two heterologous Envs diverged by 22.1%. Six months after SHIV-1157ip challenge, RAt-9 was rechallenged intrarectally with high-dose SHIV-1157ipd3N4, a tier 2 strain ( Fig. 1a) [19] .
Here we describe possible correlates of protection in RAt-9 that was followed prospectively for more than 5 years. Our results suggest that a combination of host genetics as well as innate and adaptive immune responses protected RAt-9 from the SHIV challenges and continued to contain virus despite indirect evidence of cryptic infection.
Methods

Animals
Rhesus macaque experiments were conducted according to the National Institute of Health guidelines on the care and use of laboratory animals at the AAALAC-accredited Yerkes National Primate Research Center (YNPRC, Emory University, Atlanta, Georgia, USA), and approved by the Institutional Animal Care and Use Committees of YNPRC and Dana-Farber Cancer Institute.
Virus-specific humoral immune responses
Binding antibody (Ab) titers against viral proteins were determined by ELISA [5] ; insect cell-produced HIV-C CN54 gp120 was used to avoid detecting anti-vaccinia virus Abs potentially induced by immunogen impurities. Neutralizing antibody (nAb) titers were determined by TZM-bl assay [8] . Serum antibody-dependent cellular cytotoxicity (ADCC) titers were determined using CEM-NK R cells coated with HIV-C gp120 [9] . For ADCVI, SHIV-1157ipEL-p-infected CEM-NKR-CCR5 cells were incubated with 1 : 100 diluted serum þ rhesus peripheral blood mononuclear cells (PBMC) effectors (effector : target ¼ 10 : 1) and virus replication was monitored [10, 11] .
Virus-specific cellular immune responses
Interferon (IFN)-g ELISPOT assays, intracellular cytokine staining and T-cell proliferative responses to indicated antigens were performed as described [5, 12] .
Virus replication kinetics
PBMCs were stimulated for 2 days with Concanavalin A (5 mg/ml) in the presence of rIL-2 (10 U/ml). CD8 þ cells or natural killer (NK) cells were depleted using CD8 Dynabeads (Invitrogen, Carlsbad, California, USA) or CD16-MicroBeads (Miltenyi Biotech, Gladbach, Germany), respectively. Unfractionated, CD8 þ celldepleted or NK-cell-depleted PBMCs (2 Â 10 6 ) were exposed to SHIV-1157ipEL-p (2.5 Â 10 4 TCID 50 ) and p27 levels in culture supernatants measured by ELISA. Transwell CD8 þ cell noncytotoxic antiviral response (CNAR) activity was measured as described [13] .
Major histocompatibility complex, TRIM5a and KIR3DL allele 13/14 genotyping, and gene expression analysis Major histocompatibility complex (MHC) class I genotyping was performed using one PCR primer set to amplify full-length MHC class I alleles and another to amplify only the most polymorphic region of those alleles by Sanger sequencing [14] . RAt-9 TRIM5a genotype was determined as published [15] . Heterozygosity or homozygosity for the single nucleotide polymorphism (SNP) which translates into the amino acid substitution 159H-Q unique to rhesus macaque KIR3DL alleles 13 and 14, was determined using a Step-One Plus RT PCR System/OneStep Software v2.1 (Applied Biosystems) in duplicate [16] . DNA from three control monkeys for each H/H and H/Q genotype was also analyzed (Q/Q animals were unavailable). For gene expression analysis, total blood RNA was prepared and analyzed on rhesus macaque Genome Arrays according to Affymetrix (Santa Clara, CA) instructions. Genes differentially expressed in RAt-9 (!1.0-fold difference from mean baseline derived from the naive sibling, REm-6) were further evaluated using the David annotation tool (http://apps1.niaid. nih.gov/david) and Ingenuity Pathway Analysis (IPA).
In-vivo anti-CD8 treatment and blood transfer
Four-month old infant rhesus macaques were treated with anti-CD8 mAb (cM-T807) subcutaneously (10 mg/kg) on day À4 and i.v. (5 mg/kg) on days À1, 3 and 6. Blood (10 ml) was transferred from RAt-9 to each infant by slow i.v. infusion on day 0.
Results
Long-term immune reactivity of RAt-9 Vaccinee RAt-9 remained aviremic after an initial lowdose SHIV-1157ip challenge. At that time, RAt-9 displayed peripheral blood T-cell reactivity to HIV Tat and SIV Gag [5] , nAb activity against this first challenge virus and strong HIV-C Env-directed ADCC (Fig. 1b and c). Six months after the first challenge, RAt-9 resisted high-dose intrarectal SHIV-1157ipd3N4 rechallenge, a tier 2 late-stage SHIV-1157ip derivative; at the time of SHIV-1157ipd3N4 rechallenge, RAt-9 had maintained high nAb activity against SHIV-1157ip (but none against SHIV-1157ipd3N4) and showed strong ADCC and ADCVI activities. ELISPOT reactivity to SIV Gag and HIV Tat increased after the initial SHIV-1157ip challenge (Fig. 1c ) [5] .
For more than 5 years, viral sequences were never seen [RT-PCR of plasma (detection limit, 50 copies/ml [17, 18] ) at 1-2-month intervals throughout; inguinal lymph node biopsy at month 8.5; DNA PCR of inguinal lymph node and rectal biopsies at month 52] -yet RAt-9 has maintained unusually high levels of both humoral and cellular virus-specific immunity (Fig. 1b, c , e and f), including nAbs against SHIV-1157ipEL-p (Env homologous to SHIV-1157ip [7] ) and cross-clade reactivity to SHIV SF162P4 . RAt-9 never generated nAbs against the second virus, SHIV-1157ipd3N4 [19] . ADCC and ADCVI activities were also maintained.
Specific T-cell immunity remained high as shown by IFN-g ELISPOTs after stimulation with SIV Gag or HIV Tat peptides, or with p11C, the Mamu A Ã 001 immunodominant Gag peptide (Fig. 1c) ; epitope mapping revealed five Gag regions recognized ( Fig. 1g ). At 51 months postexposure, polyfunctional reactivity was evident in both central memory and effector memory CD8 þ T cells (Fig. 1e) , and both CD4 þ and CD8 þ T cells showed strong proliferative responses to SIV Gag (Fig. 1f) .
Cryptic clade C simian/human immunodeficiency virus infection with unknown viral reservoir
Long-term maintenance of virus-specific immunity in RAt-9 suggested chronic antigenic stimulation from undetectable reservoir(s). Moreover, RAt-9 showed cellular immunity to nonvaccine-related neoantigens, SIV Nef and HIV Rev ( Fig. 1c and f) . The latter is a regulatory protein required for late-stage structural protein expression that has never been detected in virions (Dr Barbara Felber, NCI, Frederick, Maryland; personal communication). Specific T-cell recognition of Rev could only have arisen from cryptic target-cell infection followed by MHC class I presentation of Rev peptides. Thus, Rev-targeted T-cell reactivity confirms cryptic infection in RAt-9.
To date, RAt-9 has maintained normal levels of both peripheral CD4 þ memory T cells and gut CD4 þ T cells (data not shown). Importantly, CD8 þ cell-depleted PBMC of RAt-9 supported SHIV-1157ipEL-p replication (encoding env of SHIV-1157ip [7] ) ( Fig. 2a) ; detection of soluble CD8 þ CNAR activity in separate experiments (Fig. 2b) suggest CNAR played a role in the CD8 þ -cell suppressive effects.
In efforts to reveal infectious virus, blood was transferred from RAt-9 into two infant macaques, whose immature immune systems make them highly susceptible to lentiviruses [19, 20] . To enhance the recipients' susceptibility to infection, anti-CD8 mAb treatment was used to temporarily deplete CD8 þ T and NK cells [21] [22] [23] [24] ; despite profound CD8 þ -cell depletion, no viremia ensued (Fig. 2c) .
Major histocompatibility complex class I, TRIM5a and KIR3DL allele 13/14 genotyping
Genotyping was performed to test for previously described favorable MHC class I alleles; RAt-9 was MHC class I Mamu-A1 Ã 001 þ , B Ã 008 -, B Ã 017and expressed a B13 serotype (Mamu-B Ã 041 þ , B Ã 048 þ and B Ã 064 þ ; [25] ) previously associated with delayed SIV disease progression [26] . Interestingly, RAt-9 also displayed a B11a serotype (allelic expression of Mamu-B Ã 012, B Ã 030 and B Ã 038), associated with rapid disease progression in SIVmac239infected rhesus macaques [26] .
Expression of KIR3DL alleles 13 and/or 14 in NK cells, and identification of an associated SNP that results in a Q at AA position 159 instead of a consensus H in the other identified alleles, were shown to play a role in innate immunity-mediated protection against immunodeficiency virus infection in rhesus macaques [16] . RAt-9 and her sibling (REm-6) showed homozygous KIR3DL H/H allele expression ( Fig. 2d ). RAt-9 also expressed homozygous TRIM5a TFP/TFP alleles; both allelic expression patterns of KIR3DL and TRIM5a have been correlated with protection from SIV infection [15, 16, 27] . Peripheral blood gene expression profiling of RAt-9 (using REm-6 for baseline corrections) also showed differential expression of genes involved in cell-mediated immunity, MHC class I pathways, inflammatory responses, and the KIR3 family ( Fig. 2e ).
Discussion
RAt-9, vaccinated with recombinant protein immunogens, remained aviremic after sequential SHIV-C challenges, including high-dose SHIV-1157ipd3N4 challenge. Our earlier data suggested that the initial virus exposure boosted vaccine-induced cellular immunity via sub-threshold infection kept in check by vaccine-induced humoral immunity; boosted cellular responses then prevented infection with the more aggressive second virus. Here we report that strong nAb, ADCC and ADCVI activities likely contributed to overall protection; MHC haplotype and innate immunity via enhanced KIR expression and CNAR activity were potential cofactors in viral containment; RAt-9 maintained high-level SHIV-C-directed humoral and T-cell immunity for more than 5 years after first virus exposure and developed neo-antigen reactivity; blood transfer from RAt-9 to CD8 þ cell-depleted infant rhesus macaques revealed no replicating virus. Together, the data suggest that RAt-9 harbors an undetectable SHIV-C infection resulting in continuous viral antigen exposure at levels sufficient to maintain cellular/humoral antiviral responses that, in turn, keep virus replication below detection levels.
We considered treating RAt-9 directly with anti-CD8 mAb to temporarily deplete CD8 þ T cells and NK cells to allow resurgence of cryptic virus. However, anti-CD8 mAb treatment was contraindicated because high nAb and ADCC/ADCVI titers of RAt-9 would have blocked viral spread. We also seek to assess the natural history of vaccine-induced, live-virus-boosted antiviral immunity and CNAR activity, which transient depletion of CD8 þ cells in RAt-9 may alter [21, 24] .
Whereas the boost in vaccine-induced immunity after virus challenge may have been due to cross-presentation of antigen-antibody complexes in the absence of infection or to transient 'hit-and-run' infection [28] , the maintenance of high-level virus-specific immunity, including neoantigen reactivity, is indirect evidence of ongoing cryptic infection or at least viral protein production. However, the immune responses observed in RAt-9 are unlike those of HIV-infected, highly active antiretroviral therapy (HAART)-treated patients, where viremia levels become undectable and cellular immunity drops despite persistent latent virus infection [29, 30] . Furthermore, if low-level virus replication provides antigen stimulation that maintains virus-specific immunity in RAt-9, we found no evidence of SIV Gag p11c T-cell epitope escape that can occur with chronic immunodeficiency virus infection [31] , as p11c reactivity was maintained. Of note, RAt-9 had no evidence of autoimmunity (data not shown).
Correlations between genetic factors and/or innate immunity, and protection from infection and/or disease progression have been identified in both HIV-exposed humans and lentivirus-exposed primates [32] [33] [34] [35] [36] [37] [38] [39] ; of those tested in RAt-9, we identified favorable TRIM5a and KIR3DL allelic expression, a B13 serotype and CNAR reactivity. The relative contribution of each to vaccine-induced protection in RAt-9 is unknown but the high levels of adaptive immune responses maintained in the animal suggest strong roles for both humoral and cellular immunity.
